1-15 of 361
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
CME/CE Virtual EventToday’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 24, 2026
06:00 PM - 07:00 PM ET
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
- advertisement
Secondary Stroke Prevention: Antithrombotic Strategies for Neurologists, Hematologists, and Cardiologists
CME/CESecondary Stroke Prevention: Antithrombotic Strategies for Neurologists, Hematologists, and Cardiologists
Deborah Siegal, MD, MSc, FRCPC
Geoffrey Barnes, MD, MSc
Mike Sharma, MD, MSc, FRCPC
Jeffrey Weitz, MD
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CME/CECELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
Sagar Lonial, MD, FACP
Saad Z. Usmani, MD, MBA
Natalie S. Callander, MD
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
MinuteCE®Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Saad Z. Usmani, MD, MBA
Natalie S. Callander, MD
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
MinuteCE®Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Saad Z. Usmani, MD, MBA
- advertisement
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
MinuteCE®Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Saad Z. Usmani, MD, MBA
Natalie S. Callander, MD
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
CME/CEMenin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Amer Zeidan, MBBS
Ghayas Issa, MD
Kathleen N. Moore, MD
Ritu Salani, MD
